

## BG SALES-TRADING MORNING DU 04/03/2016

LA SEANCE DE LA VEILLE									
INDICES U.S & JAPON			SECTEURS S&P : BEST PERFS				SECTEURS STOXX : BEST PERFS		
Indices	Cloture	Var %	Var 17h30-22H (en %)	S&P	Var %	YTD	STOXX	Var %	YTD
DJ	16943,9	0,3%	0,6%	Auto	2,3	-6,8	Basic Resources	1,4	9,1
NASDAQ	4707,4	0,1%	0,6%	MEDIAS	1,5	1,3	Auto & Part	1,1	-11,5
S&P 500	1993,4	0,3%	0,6%	Oil & Gaz	1,3	0,2	Oil & Gas	1	2,5
NIKKEI	17014,8	0,3%	-	Food Bev & Tobacco	1	2,8	Const. & Materials	1	-3,5
				SECTEURS S&P : WORST PERFS.			SECTEURS STOXX : WORST PERFS		
				S&P	Var %	YTD	STOXX	Var %	YTD
				PHARMA.	-0,7	-7,9	Travel & Leisure	-2,6	-7,3
				Food staples, Retail	-0,5	-0,4	Healthcare	-2,4	-11,2
				Consumer Serv.	-0,5	-1,5	Technology	-1,4	-7,6
				IT, SOFTW & Serv.	-0,4	-3,3	Personal & Household	-1,2	-2,1

Valeurs les plus traitées hier vs. Moy. 3M									
CAC 40			EURO STOXX 50			STOXX 600			
Stocks*	Last	Var%	Stocks*	Last	Var%	Stock*s	Last	Var%	
ARCELORMITTAL	4,3	3,1	TELEFONICA SA	9,8	0,2	EVONIK INDUSTRIES AG	24,9	-12	
ACCOR SA	39,5	-1,6	INTESA SANPAOLO	2,6	4	AGGREKO PLC	1008	12,6	
KLEPIERRE	40	1,6	L'OREAL	153,2	-1,6	OC OERLIKON CORP AG-REG	9,8	1,9	
UNIBAIL	46,9	2,8	BANCO SANTANDER SA	4	0	ARKEMA	63	8,8	
L'OREAL	153,2	-1,6	DEUTSCHE BANK AG-REGISTERED	17,6	2,7	ICAP PLC	470,3	4,2	

**DEFINITION :** \* compare les capitaux traités sur une valeur la veille rapportés à la moyenne des capitaux traités ces 3 derniers mois sur la valeur.

TAUX U.S				DEVICES				MAT. PREMIERES			
Taux U.S	Valeur	Var%	Yld	Devises	Valeur	Var%	YTD	Mat. Prem	Valeur	Var%	YTD
U.S 2 ANS	99,8	0%	0,8%	€/ \$	1,0953	0%	0,9%	BRENT	36,9	0,9%	3,3%
U.S 10 ANS	98,1	0%	1,8%	€/ ¥	124,64	-0,1%	4,8%	ONCE OR (\$)	1262,7	-0,1%	19%
VIX Index	16,7		-2,3%	VSTOXX Index	26,5		-2,2%				

### Markets Recap (source Street account)

**Asian markets are trading mixed on Friday.** Volatility is subdued with few directional drivers at play. Trading is likely being defined by anticipation/caution ahead of tonight's US jobs report and China's NPC, which begins on Saturday and sees officials roll out 2016 economic targets. Newsflow has been fairly quiet otherwise with mainland commentary again noting concerns about overheating property prices. Greater Chinese markets are mixed with the mainland lagging. The PBoC fixed the yuan midpoint higher as it conducted a weekly liquidity drain of CNY840B. There was muted reaction on the Nikkei to data showing a rebound in Japanese wages. In-line Aussie retail sales were also shrugged off ASX investors. As has been the case in recent times, miners are headlining gains amid the ongoing bounce in commodities.

**US equities closed higher in uneventful trading today.** Treasuries were stronger with some curve flattening. The dollar was weaker overall, though little changed on the yen cross. Gold was higher, with some possible support from a JP Morgan asset-allocation recommendation. Oil was little changed after a volatile day, with WTI settling (0.3%).

**It was another quiet session today, with the various macro developments having little or no effect on the price action.** The ISM non-manufacturing index was largely in line, with business activity up but employment down. Initial jobless claims came in higher than consensus, but the four-week average remained near cycle lows. The impact from these releases may have been muted by anticipation of tomorrow morning's nonfarm payrolls report.

**Energy led, with E&Ps seeing another outsized day.** Banks were better. Machinery and transports boosted industrials. Autos outperformed. Precious metal names were stronger. The "FANG" complex was weaker within tech. Healthcare was the worst performer, with biotech lagging.

### Stocks Factor to watch today :

**Indra Sistemas:** delivers counter-improvised explosive devices lab to the European Defense Agency

**Bureau Veritas / Dassault Systèmes:** both companies partner to drive digital transformation for marine and offshore companies

### Rating & TP Changes



**Adidas:** TP raised to EUR110 vs. EUR100, Outperform reiterated, @ Cowen

**Adidas:** TP raised to EUR107 vs. EUR98, Buy reiterated, @ UBS

**Adidas:** TP raised to EUR100 vs. EUR85, Equal-weight reiterated, @ Barclays

**CRH:** TP raised to EUR30 vs. EUR29, Buy reiterated, @ Berenberg

**Indra Sistemas:** TP raised to EUR13.5 vs. 11.5, Buy reiterated, @ Goldman



**Luxottica:** TP cut to EUR43.8 vs. EUR53.7, Sell reiterated, @ Goldman

**Hugo Boss:** TP cut to EUR55 vs. EUR82, Equal-weight reiterated, @ Barclays

**Richemont:** TP cut to CHF83 vs. CHF86, Buy reiterated, @ HSBC

### Bryan Garnier ... Today's comment(s)

#### Gameloft

RATING : BUY

Fair Value EUR6.7 (-11%)

At yesterday's closing price, the stock is trading 3.9% above Vivendi's last offer of EUR7.2. Gameloft's Board of Directors should give its decision soon. As the approach is considered as hostile, the company is also likely to reject this bid. As a reminder, our Fair Value of EUR6.7 was a minimum price in the case of a takeover offer. The first bid (EUR6) was too low, while the new bid is attractive (EUR7.2). However, as Vivendi is seeking to acquire Ubisoft, which has to be a friendly move, it must be generous with Gameloft (the Guillemot family runs both companies). As a result, we believe everything remains possible. **Positive.**

#### Gemalto

RATING : NEUTRAL

Fair Value EUR69 (+17%)

Gemalto has posted FY sales broadly in line with our estimate and that of the consensus but with lower than expected IFl growth. Payment, M2M, Security and e-Government showed growth but no improvement was seen in the SIM business and related services. Profit from operations (PFO) was in line with estimates but at the low-end of the vague "double digit growth" guidance (+10.4% reported). However, IFRS current EBIT, EBIT, net profit and restated EPS were significantly below our forecasts (by 2%, 18%, 27% and 7% respectively). Management gave its first annual PFO guidance, which is still vague, stating that it expects to generate a 1.5% point increase in adjusted gross margin, accelerating its PFO expansion towards its 2017 objective of over EUR660m. => **Negative.**

#### Galapagos

RATING : BUY

Fair Value EUR63 (+58%)

Galapagos reported FY2015 results in line with expectations. At the end of the year, cash position stood at EUR348m (primarily driven by the successful USD275m NASDAQ IPO. Note that following the closing of the deal on filgotinib with Gilead, The company enters 2016 with a EUR1.02bn cash position (EUR18 of our fair value). Cash burn guidance below expectations at EUR100-120m for 2016. Current share price undervalues filgotinib which should report 20w data in Crohn's disease in April as well as the Cystic Fibrosis platform.